Connect with us

Media & Technology

Goff Corp (OTCMKTS: GOFF) Major Runner as Powerful Reverse Merger SPAC Gains Traction

Published

on

Goff Corp (OTCMKTS: GOFF) is making a powerful move up the charts currently trading a few pennies off its all-time highs of $0.2641. Currently under heavy accumulation GOFF has quickly attracted a fast-growing shareholder base including some big players in small caps who have been busy buying up the float. The stock is among the most exciting stocks in small caps and has been ever since Geroge Sharp got involved. GOFF is looking to break out of its current trading range and blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension; a break over $0.2641 and its blue skies ahead. Investors are waiting for all filings to be submitted to OTCMarkets and a move to “pink current” and then the real action of RM can begin. Rumors are a well-known private crypto Company may RM into GOFF but nothing haz been confirmed. 

GOFF has been in play ever since David Lazar got involved back in June 2020, the run accelerated on June, 9, 2021 when reverse merger RM Whizz George Sharp got involved earlier this year. Mr. Sharp recently gained fame on the historic TSNP rise from triple zeroes to multi dollars trading hundreds of millions in dollar volume per day, he also took FORW from under a penny to over $1 highs. GOFF currently has massive liquidity and some of the top traders in small caps behind it who are looking for another TSNP style run. Since George Sharp gained full custodianship of GOFF things have been moving forward quickly on the road to “pink current status” and a merging Company to be announced. Reverse Merger stocks (RM) are easily among the most exciting and explosive stocks in small caps rivaling only biotech’s in their ability to make historic gains.  

Goff Corp (OTCMKTS: GOFF) currently operating out of New York, NY is a clean shell with 0 debt and a perfect merger candidate that was a David Lazar SPAC before George Sharp was awarded Custodianship on June 9th, 2021. The Company was incorporated on July 12, 2010 under the laws of the state of Nevada. With principal offices located at 9 NOF Commercial Centre Industrial Park, Old Mallow Rd, Cork City, Ireland.  

David Lazar; the King of OTC SPAC’s!! GOFF comes from David Lazar a private investor and since February of 2018, Mr. Lazar has been the managing member of Custodian Ventures LLC, where he specializes in assisting distressed public companies. Since March 2018, David has acted as the managing member of Activist Investing LLC, which specializes in active investing in distressed public companies. David has a diverse knowledge of financial, legal and operations management; public company management, accounting, audit preparation, due diligence reviews, and SEC regulations.  

In recent years there have been a number of hugely successful David Lazar custodianship/SPAC RM deals that have even spawned the message board; David Lazar, OTC SPAC’s/CUSTODIAN Plays on Investorshub.com.  Investor Sentiment in GOFF is high. 

To Find out the inside Scoop on GOFF Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

GOFF

Microcapdaily was one of the first on the scene as TSNP was taking off reporting on the stock on November 15, 2020 when TSNP was trading at $0.003 stating at the time: “TSNP is making a spectacular run up the charts in recent weeks quickly transforming into a volume leader and one of the top most traded stocks in small caps. TSNP started off in triple zero land but has gone parabolic since than quickly attracting legions of new shareholders who continue to bid the stock higher. Reverse Merger stocks (RM) are easily among the most exciting and explosive stocks in small caps rivaling only biotechs in their ability to make historic gains. TSNP is the perfect merger candidate; a clean shell with virtually no debt and the new Company HUMBL is a major mobile payments player with a first-class management team with team members coming from companies like Western Union, Moneygram, Visa, American Express, Epson, Microsoft, Facebook and Qualcomm and was recently named a Forbes “Rising Startups to Watch” The whole deal is being shepherded by George Sharp, a reverse merger whizz and someone known for doing it right. The merger is being shepherded by well-known OTC Markets analyst, George Sharp, who brought the parties together and has provided valuable advice on strategies and compliance to complete the transaction.” We concluded “The whole deal is being shepherded by George Sharp, a reverse merger whizz and someone known for doing it right.”

GOFF original business plan was to provide web-based services that focus around its website that will operate as a link for employers in and individuals seeking employment in the UK and Ireland. As stated in the only 10k the Company ever filed back in 2012: “We intend to differentiate ourselves from our competition by taking advantage of social media tools both to spread awareness and to create user friendly applications (i.e. allow job seekers to get updates via Tweets for new jobs in given fields and locations, share jobs with friends or recommend a friend to an employer on Facebook). We also intend to create an interface to allow for employers and job seekers to conduct interviews via video conferencing and applications for popular mobile devices. We believe this to be an area that will allow us to offer additional services in the future and create new revenue streams.” 

On 11 of July 2020, Custodian appointed David Lazar as the Company’s Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer and Chairman of the Board of Directors. George Sharp was awarded Custodianship on June 9th, 2021 and was appointed as the Company’s Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer and Chairman of the Board of Directors.  

For more on GOFF Subscribe Right Now!

GOFF is making a powerful move up the charts currently trading a few pennies off its all-time highs of $0.2641. Currently under heavy accumulation GOFF has quickly attracted a fast-growing shareholder base including some big players in small caps who have been busy buying up the float. The stock is among the most exciting stocks in small caps and has been ever since Geroge Sharp got involved. GOFF is looking to break out of its current trading range and blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension; a break over $0.2641 and its blue skies ahead. Investors are waiting for all filings to be submitted to OTCMarkets and a move to “pink current” and then the real action of RM can begin. Rumors are a well-known private crypto Company may RM into GOFF but nothing haz been confirmed. GOFF has been in play ever since David Lazar got involved back in June 2020, the run accelerated on June, 9, 2021 when reverse merger RM Whizz George Sharp got involved earlier this year. Mr. Sharp recently gained fame on the historic TSNP rise from triple zeroes to multi dollars trading hundreds of millions in dollar volume per day, he also took FORW from under a penny to over $1 highs. GOFF currently has massive liquidity and some of the top traders in small caps behind it who are looking for another TSNP style run. Since George Sharp gained full custodianship of GOFF things have been moving forward quickly on the road to “pink current status” and a merging Company to be announced. Reverse Merger stocks (RM) are easily among the most exciting and explosive stocks in small caps rivaling only biotech’s in their ability to make historic gains. We will be updating on GOFF when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GOFF.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in GOFF either long or short and we have not been compensated for this article

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.